中文

华大基因 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-25
ItemAmountY/Y
Revenue¥0.81B+20.4%
Gross profit¥0.32B
Operating income¥-0.01B
Net income¥-0.01B
Gross margin39.7%Net margin -1.2%
Revenue Q/Q-21.6%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.49B60.3%
R&D¥0.09B11.0%
SG&A¥0.22B27.6%
Tax & other¥0.00B0.0%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

英科医疗中科信息电连技术隆盛科技英搏尔朗新科技海特生物中石科技艾德生物智动力赛意信息创业黑马

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies